Updated: February 17, 2026

Qulipta Shortage: What Providers and Prescribers Need to Know in 2026

Author

Peter Daggett

Summarize with AI

Qulipta Availability: A Provider Briefing for 2026
Current Supply Status
Timeline and Regulatory Context
Prescribing Implications
Availability Picture
Cost and Access Resources
Tools and Resources for Providers
Alternative CGRP Options
Looking Ahead
Final Thoughts

A provider briefing on Qulipta availability in 2026. Covers supply status, prior authorization, cost barriers, alternative CGRP options, and patient access tools.

Qulipta Availability: A Provider Briefing for 2026

Qulipta (Atogepant), AbbVie's oral CGRP receptor antagonist for migraine prevention, has become a cornerstone of modern migraine management. However, providers continue to field patient complaints about difficulty filling prescriptions. This briefing covers the current availability landscape, prescribing considerations, and resources to help your patients access Qulipta in 2026.

Current Supply Status

As of early 2026, Qulipta is not listed on the FDA Drug Shortage database. There are no known manufacturing disruptions or active recalls. AbbVie continues to produce all three tablet strengths (10 mg, 30 mg, 60 mg) without reported supply constraints.

The availability issues patients experience are driven primarily by pharmacy-level stocking decisions and insurance access barriers rather than upstream supply problems. This is an important distinction when counseling patients who believe the drug is "in shortage."

Timeline and Regulatory Context

September 2021: FDA approval for preventive treatment of episodic migraine in adults
March 2023: Expanded indication for chronic migraine prevention
September 2025: Patent challenge eligibility (NCE-1 date), though no ANDA has been approved
January 2026: WAC updated to $1,204.57 per 30-day supply

No generic version of Atogepant is currently available or imminent. Providers should plan for brand-name-only access for the foreseeable future.

Prescribing Implications

Dosing Considerations

Qulipta dosing depends on indication and patient-specific factors:

Episodic migraine: 10 mg, 30 mg, or 60 mg once daily
Chronic migraine: 60 mg once daily
With strong CYP3A4 inhibitors: 10 mg once daily (episodic); avoid use (chronic)
With CYP3A4 inducers: 30 mg or 60 mg (episodic); avoid use (chronic)
With OATP inhibitors: 10-30 mg (episodic); 30 mg (chronic)
Severe renal impairment/ESRD: 10 mg (episodic); avoid use (chronic)

These dose modifications are clinically relevant and should be documented in prior authorization requests, as insurers may question the prescribed strength. For complete interaction details, see: Qulipta Drug Interactions: What to Avoid.

Prior Authorization Requirements

Virtually all commercial and Medicare Part D plans require prior authorization for Qulipta. Common PA criteria include:

Confirmed diagnosis of episodic or chronic migraine
Trial and failure of at least 1-2 oral generic preventive agents (e.g., Topiramate, Propranolol, Amitriptyline, Valproate)
Documentation of migraine frequency and disability

Some plans also require step therapy through a CGRP injectable before approving an oral gepant. Proactive documentation of prior treatment failures in clinical notes will streamline the PA process.

Monitoring

Qulipta does not carry a boxed warning. However, providers should be aware of:

Hypertension: New-onset or worsening hypertension has been reported. Monitor blood pressure.
Raynaud's phenomenon: Rare cases reported post-marketing.
Hepatotoxicity: Liver enzyme elevations have occurred. Consider baseline and periodic LFTs in patients with hepatic risk factors.
Hypersensitivity: Serious reactions including angioedema have been reported.

Availability Picture

The primary barriers to patient access are:

Pharmacy stocking: Many retail pharmacies do not routinely stock Qulipta due to its high unit cost and narrow patient volume. Specialty and mail-order pharmacies are more reliable sources.
Insurance delays: PA processing can take 5-14 business days. During this window, pharmacies may not order the drug, creating a perceived availability gap.
Cost for uninsured patients: At $1,200+ per month, cash-pay patients face a significant barrier without savings programs.

Cost and Access Resources

AbbVie provides several support programs:

Qulipta Complete Savings Card: Eligible commercially insured patients may pay as little as $0 per month. Patients can receive up to 2 fills at no charge while PA is pending.
myAbbVie Assist: Patient assistance program for uninsured/underinsured patients with qualifying financial need.
Provider support line: 1-855-QULIPTA (1-855-785-4782)

Providers can also direct patients to discount programs like GoodRx (as low as $1,109/month) and SingleCare (approximately $1,018/month) for cash-pay pricing.

For a patient-facing guide on costs: How to Save Money on Qulipta in 2026.

Tools and Resources for Providers

Medfinder for Providers offers real-time pharmacy availability data, enabling your office to verify stock before sending prescriptions. This reduces patient frustration and phone calls back to your office about unfilled prescriptions.

Additional resources:

AbbVie HCP portal: quliptahcp.com — access PA support, clinical resources, and savings program enrollment
FDA label: accessdata.fda.gov — most current prescribing information (revised March 2025)

Alternative CGRP Options

When Qulipta is inaccessible or contraindicated, consider these alternatives:

Nurtec ODT (Rimegepant): Oral gepant, 75 mg every other day for prevention. Also approved for acute treatment. Similar PA requirements.
Aimovig (Erenumab): SC injection, 70 mg or 140 mg monthly. Targets CGRP receptor.
Ajovy (Fremanezumab): SC injection, 225 mg monthly or 675 mg quarterly. Targets CGRP ligand.
Emgality (Galcanezumab): SC injection, 120 mg monthly (240 mg loading). Targets CGRP ligand. Also approved for episodic cluster headache.

Insurance formulary position varies by plan and may favor one CGRP agent over others. Check plan-specific formularies when selecting alternatives.

Looking Ahead

Several developments may affect Qulipta access in the near term:

Generic competition: Patent challenges became eligible in September 2025. While no ANDA has been approved, generic entry could occur within 1-3 years, potentially lowering costs and improving availability.
Formulary evolution: As CGRP medications mature and competition increases, insurers may reduce PA barriers for oral gepants, improving first-line access.
Post-marketing data: Growing real-world evidence may support expanded use and simplified PA criteria.

Final Thoughts

Qulipta remains a valuable option for migraine prevention in 2026. While it is not in formal shortage, pharmacy-level availability gaps and insurance barriers persist. Providers can improve patient outcomes by proactively documenting treatment history for PA submissions, directing patients to Medfinder for Providers for pharmacy availability, and connecting patients with AbbVie's savings programs.

For patient-facing resources to share with your migraine patients:

Frequently Asked Questions

No. As of early 2026, Qulipta is not listed on the FDA Drug Shortage database. Availability issues are driven by pharmacy stocking decisions and insurance access barriers, not manufacturing or supply chain problems.

Most commercial and Medicare Part D plans require a confirmed migraine diagnosis and documented trial/failure of at least 1-2 oral generic preventive agents (e.g., Topiramate, Propranolol, Amitriptyline). Some plans also require step therapy through a CGRP injectable before approving oral gepants.

For episodic migraine, reduce Qulipta to 10 mg once daily when used with strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin). For chronic migraine, avoid concomitant use with strong CYP3A4 inhibitors altogether. Similar caution applies with OATP inhibitors like cyclosporine.

Direct patients to Medfinder (medfinder.com/providers) for real-time pharmacy stock data. Recommend specialty or mail-order pharmacies, which are more likely to stock Qulipta. Help patients enroll in the Qulipta Complete Savings Card (1-855-785-4782) to reduce cost barriers, and ensure PA is submitted promptly to avoid dispensing delays.

Medfinder Editorial Standards

Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.

Read our editorial standards